Valuation: Adial Pharmaceuticals, Inc.

Market Cap 8.68M 7.52M 7.01M 6.45M 12.17M 826M 12.31M 82.37M 32.33M 413M 32.61M 31.89M 1.37B P/E 2026 *
-2.68x
P/E 2027 * -0.54x
Enterprise Value 8.68M 7.52M 7.01M 6.45M 12.17M 826M 12.31M 82.37M 32.33M 413M 32.61M 31.89M 1.37B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
95.68%
Yield 2026 *
-
Yield 2027 * -
1 day+6.58%
1 week+28.57%
Current month+21.26%
1 month+39.66%
3 months+153.12%
6 months+18.25%
Current year-26.36%
1 week 3.2
Extreme 3.2
4.2
1 month 2.5
Extreme 2.5
4.2
Current year 1.31
Extreme 1.31
6.75
1 year 1.31
Extreme 1.31
10.75
3 years 1.31
Extreme 1.31
162.5
5 years 1.31
Extreme 1.31
3,175
10 years 1.31
Extreme 1.31
5,900
Manager TitleAgeSince
Chief Executive Officer 66 2022-08-17
Director of Finance/CFO 63 2024-11-15
Chief Operating Officer 61 2024-01-17
Director TitleAgeSince
Director/Board Member 76 2015-01-31
Director/Board Member 46 2014-08-31
Chairman 58 2022-08-17
Date Insider Type Main position Quantity % Market Cap.
5/29/25 Free

Chief Operating Officer

94,000 1.4518%
5/29/25 Free

Director

28,000 0.4325%
5/29/25 Free

Chief Executive Officer

138,000 2.1314%
Change 5-day change 1-year change 3-year change Capi.($)
+6.58%+28.57%-62.67%-97.26% 8.68M
+1.26%-0.25%+4.29%+16.03% 48.57B
+1.98%+9.05%+413.94%+532.17% 41.95B
+3.44%-4.65%+28.34%+8.81% 38.85B
+1.40%+0.10%+6.61%+61.93% 37.24B
+2.42%+5.72%+12.38%+44.79% 30.67B
-0.16%-3.11% - - 16.1B
+2.20%+0.48%+34.71%+127.15% 16.41B
+0.83%+2.42%+8.76%+19.65% 13.97B
+4.25%-8.23%-1.49%-35.46% 12.62B
Average +2.42%+2.16%+49.43%+75.31% 25.64B
Weighted average by Cap. +1.96%-0.12%+83.12%+120.84%

Financials

2026 *2027 *
Net sales - -
Net income -14.28M -12.37M -11.53M -10.6M -20.02M -1.36B -20.24M -135M -53.17M -679M -53.63M -52.44M -2.25B -21.14M -18.31M -17.07M -15.7M -29.63M -2.01B -29.96M -201M -78.71M -1.01B -79.39M -77.64M -3.33B
Net Debt - -
Logo Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead program is AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis. AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. AT177's active ingredient is a prodrug of indirubin, a potent AhR agonist within indigo naturalis, a botanical extract with clinical efficacy in ulcerative colitis. AT177's colon-targeted formulation delivers therapeutic AhR engagement directly to the colonic mucosa with exquisite gut restriction, minimizing the systemic AhR exposure associated with adverse effects. Its historical investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients.
Employees
5
Date Price Change Volume
26-08-05 US$4.050 +6.58% 116,909
26-08-04 US$3.800 +4.40% 122,069
26-08-03 US$3.640 +8.98% 100,008
26-07-31 US$3.340 +1.52% 51,603
26-07-30 US$3.290 +4.44% 99,337
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.050USD
Average target price
8.333USD
Spread / Average Target
+105.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADIL Stock